Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies for Relapsing and Primary Progressive Multiple Sclerosis
Shots:
- The P-III OPERA- ORATORIO and OBOE studies result involves assessing of Ocrevus (ocrelizumab) vs PBO in patients with RMS and PPMS- presented at AAN Annual Meeting
- Results: reduction in risk of disability progression associated with exposure and lower B-cell levels & permanent disability progression; @24wks. reduction in CDP; @48wks. RMS- PPMS patients with CDP treated with Ocrevus vs switched to Ocrevus- (10.4 %- 43.7% vs 15.7%- 53.1%); @12- 24 & 52 wks. in RMS reduction in nerve cell damage- inflammation biomarker in serum and CSF
- Ocrevus (ocrelizumab- IV) is a mAb targeting CD20+ B cells- administered every 6mos. and is approved in 85 countries including NA- SA- Eastern Europe & EU for both RMS & PPMS
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com